Table 3.2 summarises the developments identified in Part 3 and shows the likely time frames in which these matters will need to be considered in a formal manner by the Jurisdictional Blood Committee and governments for their policy implications.
| Issue | Potential for impact | Likely time frame |
|---|---|---|
| Transmissible diseases | High | Immediate and ongoing |
| Testing and manufacturing | High | Medium to long |
| Blood management techniques | Medium | Medium to long |
| Patient safety | Low | Short to medium |
| New products | High | Short to medium |
| IVIg developments | High | Medium to long |
| Development of substitutes for plasma-derived products | Medium | Medium to long |
| New recombinant products | Medium | Medium |
| Market structure | Low | Medium |
| Research | Medium | Medium |
| Inquiries and legal action | Low | Medium |